(Q43225402)

English

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

scientific article published in December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A J Scheen

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

M H Tan

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

D J Betteridge

3

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

K Birkeland

4

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

O Schmitz

5

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

B Charbonnel

6

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PROactive investigators

7

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Diabetic Medicine

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1242-1249

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Oral antidiabetic agents. A guide to selection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

PROactive: time for a critical appraisal

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Standards of medical care in diabetes--2009.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Rosiglitazone RECORD study: glucose control outcomes at 18 months

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Pioglitazone: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02857.X

21 January 2018

Identifiers

10.1111/J.1464-5491.2009.02857.X

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43225402&oldid=1601456456"